NRC
BEARISH
$17.04
Live
National Research Corporation · NASDAQ
$9.76
52W Range
$22.79
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 15, 2026
Market cap
$387.6M
P/E
34.08
ROE
51.2%
Profit margin
8.4%
Debt/Equity
5.74
Dividend yield
3.29%
AI Analysis
AI-powered fundamental assessment
Confidence
95%
NRC exhibits a severe disconnect between its current market price ($17.04) and its deterministic value markers, with a Graham Number of $2.64 and an Intrinsic Value of $3.50. While the Piotroski F-Score of 6/9 suggests stable operational health, this is overshadowed by critical solvency risks including a Debt/Equity ratio of 5.74 and a Current Ratio of 0.55. Fundamental growth is in sharp decline, with YoY earnings crashing by 74.40%, and the dividend is unsustainable with a payout ratio of 104%. The recent 1-year price surge appears speculative as it contradicts the bearish technical trend and deteriorating fundamentals.
Key Strengths
Strong Gross Margin (61.88%)
High Operating Margin (32.18%)
Exceptional ROE (51.24%)
Stable Piotroski F-Score (6/9)
Strong 1-year price momentum (+63.5%)
Key Risks
Extreme overvaluation relative to Graham and Intrinsic values
Critical liquidity risk (Current Ratio 0.55)
Excessive leverage (Debt/Equity 5.74)
Severe earnings contraction (-74.40% YoY)
Unsustainable dividend payout (104%)
AI Fair Value Estimate
Based on comprehensive analysis
$3.5
-79.5% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
10
15
30
40
10
AI Verdict
High Risk / Overvalued
Key drivers: Massive valuation gap, Negative growth trajectory, Poor liquidity ratios, Unsustainable dividend
Confidence
90%
Value
10/100
Ref P/E 34.08, Graham Number $2.64
Positives
No standout positives identified.
Watchpoints
- Price/Book of 27.57 is extreme
- Current price is ~485% above Intrinsic Value
- P/E of 34.08 is high for declining earnings
Future
15/100
Ref Growth rates
Positives
- Forward P/E (14.69) suggests expected recovery
Watchpoints
- Revenue growth is negative (-4.60%)
- Earnings growth is crashing (-74.40%)
Past
30/100
Ref Historical trends
Positives
- Recent 1Y price recovery
Watchpoints
- 5Y change is -58.9%
- Consistent earnings misses in recent quarters
Health
40/100
Ref Piotroski F-Score, Debt/Equity
Positives
- Piotroski F-Score 6/9 indicates stability
Watchpoints
- Debt/Equity 5.74 is dangerously high
- Current Ratio 0.55 indicates inability to cover short-term liabilities
Dividend
10/100
Ref Yield, Payout
Positives
- Yield of 3.29% is attractive on surface
Watchpoints
- Payout ratio of 104% means dividends exceed earnings
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$17.04
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NRC and closest competitors.
Updated 2026-04-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NRC
National Research Corporation
Primary
|
-58.9% | -57.9% | +63.5% | +50.6% | -1.2% | 0.0% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
IRD
Opus Genetics, Inc.
Peer
|
+2.3% | -0.9% | +654.9% | +173.5% | +7.0% | +17.8% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
ENTA
Enanta Pharmaceuticals, Inc.
Peer
|
-71.8% | -64.9% | +208.7% | +21.9% | -0.9% | +6.2% |
NRC
National Research Corporation
Primary
5Y
-58.9%
3Y
-57.9%
1Y
+63.5%
6M
+50.6%
1M
-1.2%
1W
0.0%
AKB
Akebia Therapeutics, Inc.
Peer
5Y
-59.4%
3Y
+113.8%
1Y
-13.6%
6M
-50.5%
1M
-5.8%
1W
+15.0%
IRD
Opus Genetics, Inc.
Peer
5Y
+2.3%
3Y
-0.9%
1Y
+654.9%
6M
+173.5%
1M
+7.0%
1W
+17.8%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
ENT
Enanta Pharmaceuticals, Inc.
Peer
5Y
-71.8%
3Y
-64.9%
1Y
+208.7%
6M
+21.9%
1M
-0.9%
1W
+6.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
34.08
Forward P/E
14.69
PEG Ratio
N/A
P/B Ratio
27.57
P/S Ratio
2.82
EV/Revenue
3.38
EV/EBITDA
12.53
Market Cap
$387.6M
Profitability
Profit margins and return metrics
Profit Margin
8.44%
Operating Margin
32.18%
Gross Margin
61.88%
ROE
51.24%
ROA
13.73%
Growth
Revenue and earnings growth rates
Revenue Growth
-4.6%
Earnings Growth
-74.4%
Q/Q Revenue Growth
-4.64%
Q/Q Earnings Growth
-72.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
5.74
High debt
Current Ratio
0.55
Weak
Quick Ratio
0.43
Poor
Cash/Share
$0.18
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
60.4%
Op. Margin
13.3%
Net Margin
5.1%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
8.64x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
84%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-28
$N/A
2019-08-06
$0.29
+11.5% surprise
2019-05-07
$0.32
+3.2% surprise
2019-02-12
$0.3
-71.4% surprise
Healthcare Sector Comparison
Comparing NRC against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
34.08
This Stock
vs
90.61
Sector Avg
-62.4%
(Discount)
Return on Equity (ROE)
51.24%
This Stock
vs
-101.52%
Sector Avg
-150.5%
(Below Avg)
Profit Margin
8.44%
This Stock
vs
-12.47%
Sector Avg
-167.7%
(Weaker)
Debt to Equity
5.74
This Stock
vs
3.4
Sector Avg
+68.6%
(Higher)
Revenue Growth
-4.6%
This Stock
vs
124.21%
Sector Avg
-103.7%
(Slower)
Current Ratio
0.55
This Stock
vs
4.56
Sector Avg
-87.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NRC
National Research Corporation
|
BEARISH | $387.6M | 34.08 | 51.2% | 8.4% | $17.04 | |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | Compare |
|
IRD
Opus Genetics, Inc.
|
BEARISH | $381.36M | - | -242.4% | -% | $5.36 | Compare |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
BEARISH | $399.6M | - | -60.0% | -106.8% | $13.77 | Compare |
NRC
National...
BEARISH
Mkt Cap
$388M
P/E
34.1
ROE
51.2%
Price
$17.04
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | RAU JASON RUSSELL | Officer | Stock Award | 60,000 | - |
| 2026-02-17 | HARRISON SHANE R | Chief Financial Officer | Purchase | 8,000 | $98,162 |
| 2026-01-05 | HAYS MICHAEL D | Chairman of the Board | Option Exercise | 9,145 | $139,278 |
| 2025-12-15 | HRDY HELEN | Chief Operating Officer | Option Exercise | 12,346 | $188,030 |
RAU JASON RUSSELL
Officer
2026-03-12
60,000 shares
HARRISON SHANE R
Chief Financial Officer
2026-02-17
8,000 shares
·
$98,162
HAYS MICHAEL D
Chairman of the Board
2026-01-05
9,145 shares
·
$139,278
HRDY HELEN
Chief Operating Officer
2025-12-15
12,346 shares
·
$188,030
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning NRC from our newsroom.
Newest → oldest
No matching news yet.